Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran in Patients with Hereditary Angioedema
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran in Late-Breaking Oral Presentation at EAACI 2026
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran as a One-Time Treatment for Hereditary Angioedema
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran ; Hereditary Angioedema Patient-Focused Research at AAAAI 2026
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Syntholene Energy Corp. Appoints Former Suncor, Shell Operations Executive Marc Mageau to Advisory Board
